CJC-1295

Last updated

CJC-1295
CJC-1295 DAC.svg
Clinical data
Other namesCJC-1295 with DAC
Routes of
administration 		Subcutaneous injection
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C165H269N47O46
Molar mass 3647.250 g·mol−1
3D model (JSmol)
  • NC([C@H](CCCCNC(CCN1C(C=CC1=O)=O)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@@]([C@H](CC)C)([H])NC([C@@H](NC([C@H](CCC(N)=O)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CCC(N)=O)NC([C@@H](NC([C@H](CC(C)C)NC([C@H](C(C)C)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H](CO)NC([C@H](CCC(N)=O)NC([C@@]([C@@H](C)O)([H])NC([C@@H](NC([C@@]([C@H](CC)C)([H])NC([C@@H](NC([C@@H](NC([C@H](NC([C@@H](N[H])CC2=CC=C(O)C=C2)=O)C)=O)CC(O)=O)=O)C)=O)=O)CC3=CC=CC=C3)=O)=O)=O)=O)CC4=CC=C(O)C=C4)=O)=O)=O)=O)=O)C)=O)=O)=O)=O)C)=O)=O)=O)=O)=O)=O)CC(O)=O)=O)=O)=O)=O)=O)=O
  • InChI=1S/C165H269N47O46/c1-22-87(15)130(209-137(233)92(20)185-148(244)116(76-127(225)226)196-136(232)89(17)183-138(234)99(168)73-95-44-48-97(217)49-45-95)160(256)204-115(74-94-36-25-24-26-37-94)154(250)211-132(93(21)216)162(258)195-108(54-57-123(171)221)145(241)205-120(80-215)158(254)200-114(75-96-46-50-98(218)51-47-96)153(249)192-105(43-35-66-182-165(177)178)141(237)191-102(40-28-31-62-167)146(242)208-129(86(13)14)159(255)202-109(68-81(3)4)147(243)184-90(18)135(231)189-106(52-55-121(169)219)143(239)198-112(71-84(9)10)151(247)206-118(78-213)156(252)186-91(19)134(230)188-103(41-33-64-180-163(173)174)140(236)190-101(39-27-30-61-166)142(238)197-111(70-83(7)8)150(246)199-110(69-82(5)6)149(245)194-107(53-56-122(170)220)144(240)201-117(77-128(227)228)155(251)210-131(88(16)23-2)161(257)203-113(72-85(11)12)152(248)207-119(79-214)157(253)193-104(42-34-65-181-164(175)176)139(235)187-100(133(172)229)38-29-32-63-179-124(222)60-67-212-125(223)58-59-126(212)224/h24-26,36-37,44-51,58-59,81-93,99-120,129-132,213-218H,22-23,27-35,38-43,52-57,60-80,166-168H2,1-21H3,(H2,169,219)(H2,170,220)(H2,171,221)(H2,172,229)(H,179,222)(H,183,234)(H,184,243)(H,185,244)(H,186,252)(H,187,235)(H,188,230)(H,189,231)(H,190,236)(H,191,237)(H,192,249)(H,193,253)(H,194,245)(H,195,258)(H,196,232)(H,197,238)(H,198,239)(H,199,246)(H,200,254)(H,201,240)(H,202,255)(H,203,257)(H,204,256)(H,205,241)(H,206,247)(H,207,248)(H,208,242)(H,209,233)(H,210,251)(H,211,250)(H,225,226)(H,227,228)(H4,173,174,180)(H4,175,176,181)(H4,177,178,182)/t87-,88-,89+,90-,91-,92-,93+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,129-,130-,131-,132-/m0/s1
  • Key:ZUQGTWKGESAQCD-ZGFIGYLBSA-N

CJC-1295 DAC, also known as DAC:GRF (short for drug affinity complex:growth hormone-releasing factor), is a synthetic analogue of growth hormone-releasing hormone (GHRH) (also known as growth hormone-releasing factor (GRF)) and a growth hormone secretagogue (GHS) which was developed by ConjuChem Biotechnologies. [1] [2] [3] It is a modified form of GHRH (1-29) with improved pharmacokinetics, especially in regard to half-life. [1] [2] [3] [4]

Contents

Effects

CJC-1295 may markedly increase plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in animals and humans. [1] [2] [3] [5] With a single injection, in human subjects, CJC-1295 DAC may increase plasma GH levels by 2- to 10-fold for 6 days or longer and plasma IGF-1 levels by 0.5- to 3-fold for 9 to 11 days. [3] With the inclusion of the DAC additive, the drug has an estimated half-life of about 6 to 8 days in humans. [3] With multiple doses of CJC-1295, IGF-1 levels were found to remain elevated in humans for up to 28 days. [3]

CJC-1295 has been shown to extend the half-life and bioavailability of growth-hormone-releasing hormone 1-29 and stimulate insulin-like growth factor 1 secretion. It increases the half-life of acting agents by bioconjugation. [6] The extended half-life is achieved through the addition of a drug affinity complex (DAC) that binds to albumin, thus prolonging the peptide's presence in the bloodstream. [7] [8] [9] It is primarily used for its potential to stimulate the release of growth hormone (GH) from the pituitary gland. [10]

Risks

CJC-1295 was under investigation for the treatment of lipodystrophy and growth hormone deficiency and reached phase II clinical trials but was discontinued upon the death of one of the trial subjects. [11] [12] The attending physician of the trial believed that the most likely explanation for the incident was that the patient had asymptomatic coronary artery disease with plaque rupture and occlusion, and that the occurrence was unrelated to treatment with CJC-1295. [12] Research was terminated nonetheless as a precaution. [12] CJC-1295 has found grey market use for bodybuilding purposes, with this, in some countries such as the Netherlands, being an illicit use. [11] [13]

Structure

CJC-1295 and Modified GRF (1-29) is equated falsely in several scientific papers. [14] [15] CJC-1295, CJC-1295 DAC, and CJC-1295 with DAC are synonyms, while Modified GRF (1-29) , also known as CJC-1295 without DAC, lacks the C-terminus extension with Nɛ-maleimidopropionyl-Lysine, which is refered to as DAC. [16]

The IUPAC modification nomenclature for the peptide CJC-1295 is Nɛ30-maleimidopropionyl-[D-Ala2, Gln8, Ala15, Leu27]-Sermorelin-Lys30.

Sermorelin : H-Tyr-Ala2-Asp-Ala-Ile-Phe-Thr-Asn8-Ser-Tyr-Arg-Lys-Val-Leu-Gly15-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met27-Ser-Arg-NH2

CJC-1295 without DAC : H-Tyr-D-Ala2-Asp-Ala-Ile-Phe-Thr-Gln8-Ser-Tyr-Arg-Lys-Val-Leu-Ala15-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu27-Ser-Arg-NH2

CJC-1295: H-Tyr-D-Ala2-Asp-Ala-Ile-Phe-Thr-Gln8-Ser-Tyr-Arg-Lys-Val-Leu-Ala15-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu27-Ser-Arg-(Nɛ-maleimidopropionyl-)Lys30-NH2

See also

Related Research Articles

<span class="mw-page-title-main">Enfuvirtide</span> Chemical compound

Enfuvirtide (INN), sold under the brand name Fuzeon, is an HIV fusion inhibitor, the first of a class of antiretroviral drugs used in combination therapy for the treatment of AIDS/HIV.

ConjuChem Biotechnologies Inc. is a medical biotechnology company located in Montreal, Quebec, Canada which is credited with inventing the experimental peptide hormone CJC-1295.

<span class="mw-page-title-main">Motilin</span>

Motilin is a 22-amino acid polypeptide hormone in the motilin family that, in humans, is encoded by the MLN gene.

Neurophysin I is a carrier protein with a size of 10 KDa and contains 90 to 97 amino acids. It is a cleavage product of preprooxyphysin. It is a neurohypophysial hormone that is transported in vesicles with oxytocin, the other cleavage product, along axons, from magnocellular neurons of the hypothalamus to the posterior lobe of the pituitary. Although it is stored in neurosecretory granules with oxytocin and released with oxytocin, its biological action is unclear.

Growth hormone–releasing hormone (GHRH), also known as somatocrinin among other names in its endogenous form and as somatorelin (INN) in its pharmaceutical form, is a releasing hormone of growth hormone (GH). It is a 44-amino acid peptide hormone produced in the arcuate nucleus of the hypothalamus.

<span class="mw-page-title-main">Neurophysin II</span> Cleavage product of the arginine vasopressin gene

Neurophysin II is a carrier protein with a size of 19,687.3 Da and is made up of a dimer of two virtually identical chains of amino acids. Neurophysin II is a cleavage product of the AVP gene. It is a neurohypophysial hormone that is transported in vesicles with vasopressin, the other cleavage product, along axons, from magnocellular neurons of the hypothalamus to the posterior lobe of the pituitary. Although it is stored in neurosecretory granules with vasopressin and released with vasopressin into the bloodstream, its biological action is unclear. Neurophysin II is also known as a stimulator of prolactin secretion.

Tazarotene-induced gene-1 (TIG1) is a protein which has been implicated as a putative tumor suppressor. It is structurally similar to the protein latexin, which has also been shown to demonstrate some tumor suppression activity. TIG1 is thought to be a transmembrane protein, and its mechanism of tumor suppression is largely unknown.

<span class="mw-page-title-main">Growth-hormone-releasing hormone receptor</span> Receptor protein that binds with somatcrinin

The growth-hormone-releasing hormone receptor (GHRHR) is a G-protein-coupled receptor that binds growth hormone-releasing hormone. The GHRHR activates a Gs protein that causes a cascade of cAMP via adenylate cyclase. GHRHR is distinct from the growth hormone secretagogue receptor, where growth hormone releasing peptides act to release growth hormone.

Big dynorphin is an endogenous opioid peptide of the dynorphin family that is composed of both dynorphin A and dynorphin B. Big dynorphin has the amino acid sequence: Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr. It has nociceptive and anxiolytic-like properties, as well as effects on memory in mice.

Salmon calcitonin (sCT) is the type of calcitonin hormone found in salmon.

Taspoglutide is a former experimental drug, a glucagon-like peptide-1 agonist, that was under investigation for treatment of type 2 diabetes and being codeveloped by Ipsen and Roche.

α-Endorphin Chemical compound

α-Endorphin (alpha-endorphin) is an endogenous opioid peptide with a length of 16 amino acids, and the amino acid sequence: Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr. With the use of mass spectrometry, Nicholas Ling was able to determine the primary sequence of a-endorphin.

Leumorphin, also known as dynorphin B1–29, is a naturally occurring endogenous opioid peptide. Derived as a proteolytic cleavage product of residues 226-254 of prodynorphin, leumorphin is a nonacosapeptide and has the sequence Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-Arg-Ser-Gln-Glu-Asp-Pro-Asn-Ala-Tyr-Ser-Gly-Glu-Leu-Phe-Asp-Ala. It can be further reduced to dynorphin B and dynorphin B-14 by pitrilysin metallopeptidase 1, an enzyme of the endopeptidase family. Leumorphin behaves as a potent and selective κ-opioid receptor agonist, similarly to other endogenous opioid peptide derivatives of prodynorphin.

Modified GRF (1-29) often abbreviated as mod GRF (1-29), originally known as tetrasubstituted GRF (1-29), is a term used to identify a 29 amino acid peptide analogue of growth-hormone-releasing hormone (GHRH), a releasing hormone of growth hormone (GH). It is a modified version of the shortest fully functional fragment of GHRH, often referred to as growth hormone releasing factor (1-29), and also known by its standardized name, sermorelin.

Hanatoxin is a toxin found in the venom of the Grammostola spatulata tarantula. The toxin is mostly known for inhibiting the activation of voltage-gated potassium channels, most specifically Kv4.2 and Kv2.1, by raising its activation threshold.

Growth hormone secretagogues or GH secretagogues (GHSs) are a class of drugs which act as secretagogues of growth hormone (GH). They include agonists of the ghrelin/growth hormone secretagogue receptor (GHSR), such as ghrelin (lenomorelin), pralmorelin (GHRP-2), GHRP-6, examorelin (hexarelin), ipamorelin, and ibutamoren (MK-677), and agonists of the growth hormone-releasing hormone receptor (GHRHR), such as growth hormone-releasing hormone, CJC-1295, sermorelin, and tesamorelin.

<span class="mw-page-title-main">Examorelin</span> Chemical compound

Examorelin (INN) (developmental code names EP-23905, MF-6003), also known as hexarelin, is a potent, synthetic, peptidic, orally-active, centrally-penetrant, and highly selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and a growth hormone secretagogue which was developed by Mediolanum Farmaceutici. It is a hexapeptide with the amino acid sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 which was derived from GHRP-6. These GH-releasing peptides have no sequence similarity to ghrelin, but mimic ghrelin by acting as agonists at the ghrelin receptor.

Centruroides suffusus suffusus toxin II (CssII) is a scorpion β-toxin from the venom of the scorpion Centruroides suffusus suffusus. CssII primarily affects voltage-gated sodium channels by causing a hyperpolarizing shift of voltage dependence, a reduction in peak transient current, and the occurrence of resurgent currents.

<span class="mw-page-title-main">Anaritide</span> Synthetic Peptide

Anaritide is a synthetic analogue of atrial natriuretic peptide (ANP).

DKK-SP1 is one of the many neurotoxins present in the scorpion Mesobuthus martensii. This toxin inhibits the voltage-gated sodium channel Nav1.8.

References

  1. 1 2 3 Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. (July 2005). "Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog". Endocrinology. 146 (7): 3052–8. doi:10.1210/en.2004-1286. PMID   15817669.
  2. 1 2 3 Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, et al. (December 2006). "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse". American Journal of Physiology. Endocrinology and Metabolism. 291 (6): E1290-4. doi:10.1152/ajpendo.00201.2006. PMID   16822960.
  3. 1 2 3 4 5 6 Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (March 2006). "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults". The Journal of Clinical Endocrinology and Metabolism. 91 (3): 799–805. doi: 10.1210/jc.2005-1536 . PMID   16352683.
  4. ↑ Thorner MO (June 2008). "The discovery of growth hormone-releasing hormone: an update". Journal of Neuroendocrinology. 20 (6): 653–4. doi: 10.1111/j.1365-2826.2008.01740.x . PMID   18601685. S2CID   29788809.
  5. ↑ Ionescu M, Frohman LA (December 2006). "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog". The Journal of Clinical Endocrinology and Metabolism. 91 (12): 4792–7. doi: 10.1210/jc.2006-1702 . PMID   17018654.
  6. ↑ "Current Research Findings Regarding CJC-1295". Neo Scientific. 2 June 2015. Archived from the original on 7 April 2019. Retrieved 3 August 2015. The reason why CJC1295 possesses the ability to lengthen the half-life within the active agent has to do with the scientific process known as bioconjugation. This technology, which is relatively new in nature, is defined by its ability to take a reactive group and bond it to a peptide (Aslam and Dent). This attachment causes a reaction with a nucleophilic unit; a typically partially molecule that is found within the bloodstream of an animal test subject. This reaction in turn causes a more stable bond to occur. This specific peptide has an especially high attraction to albumin, a globular protein that is soluble in water. This affinity prohibits natural degradation, which in turn increases the peptide's half-life (Hermanson). Additionally, clinical research performed on animal test subjects has thus far shown that there have been no signs of DPP-IV degradation present when CJC-1295 was introduced (Gonzalez, US Peptide Articles).
  7. ↑ Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V (November 2021). "Advances in the detection of growth hormone releasing hormone synthetic analogs". Drug Testing and Analysis. 13 (11–12): 1871–1887. doi:10.1002/dta.3183. PMID   34665524.
  8. ↑ Hu ZY, Wang WJ, Hu L, Shi JH, Jiang SL (April 2024). "Comprehending the intermolecular interaction of dacomitinib with bovine serum albumin: experimental and theoretical approaches". Journal of Biomolecular Structure & Dynamics. 42 (7): 3579–3592. doi:10.1080/07391102.2023.2218926. PMID   37288787.
  9. ↑ Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. (July 2005). "Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog". Endocrinology. 146 (7): 3052–3058. doi:10.1210/en.2004-1286. PMID   15817669.
  10. ↑ Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ (December 2009). "Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects". Growth Hormone & IGF Research. 19 (6): 471–477. doi:10.1016/j.ghir.2009.03.001. PMC   2787983 . PMID   19386527.
  11. 1 2 Hartvig RA, Holm NB, Dalsgaard PW, Reitzel LA, Müller IB, Linnet K (2014). "Identification of peptide and protein doping related drug compounds confiscated in Denmark between 2007-2013". Scandinavian Journal of Forensic Science. 20 (2): 42–49. doi: 10.2478/sjfs-2014-0003 . ISSN   2353-0707.
  12. 1 2 3 ConjuChem (August 2006). "Patient Died in Lipodystrophy Drug Study". Archived from the original on 2017-11-06. Retrieved 2015-06-13.
  13. ↑ Henninge J, Pepaj M, Hullstein I, Hemmersbach P (2010). "Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation". Drug Testing and Analysis. 2 (11–12): 647–50. doi:10.1002/dta.233. PMID   21204297.
  14. ↑ Thomas A, Walpurgis K, Tretzel L, Brinkkötter P, Fichant E, Delahaut P, et al. (2015). "Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS". Drug Test Anal. 7 (11–12): 990–8. doi:10.1002/dta.1868. PMID   26382721.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  15. ↑ Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V (2021). "Advances in the detection of growth hormone releasing hormone synthetic analogs". Drug Test Anal. 13 (11–12): 1871–1887. doi:10.1002/dta.3183. PMID   34665524.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  16. ↑ Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults". J Clin Endocrinol Metab. 91 (3): 799–805. doi:10.1210/jc.2005-1536. PMID   16352683.{{cite journal}}: CS1 maint: multiple names: authors list (link)
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.